Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer patients' arms swell less after an effective lymph node transfer.

2.

A new device enhances liquid biopsy.

3.

Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.

4.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

5.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot